Trial Profile
Open label safety evaluation of specific immunotherapy in subjects aged 5-17 years suffering from seasonal rhinoconjunctivitis due to grass pollen not responding to pharmacotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 May 2006
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Adverse reactions
- 05 May 2006 New trial record.